Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.62 |
| ▸ | CHRM1 | P11229 | 5/20 | 0.62 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.62 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.62 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 8/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744418 | 0.91 | CHRM2 (0.64) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL30345524 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM5CHRM3CACNA1I | |
| SCHEMBL26089244 | 0.87 | CHRM2 (0.52) | CHRM2CHRM1CHRM5CHRM3CACNA1I | |
| SCHEMBL23744071 | 0.84 | CHRM2 (0.86) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL23744643 | 0.84 | CHRM2 (0.86) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL23744600 | 0.84 | CHRM1 (0.61) | CHRM2CHRM1CHRM5CHRM3CACNA1I | |
| SCHEMBL23744449 | 0.84 | CHRM1 (0.61) | CHRM2CHRM1CHRM5CHRM3CACNA1I | |
| SCHEMBL30345569 | 0.81 | CHRM2 (0.54) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL26086939 | 0.81 | CHRM2 (0.54) | CHRM2CHRM1CHRM5CHRM3CHRM4 | |
| SCHEMBL26430665 | 0.80 | CHRM2 (0.78) | CHRM2CHRM1CHRM5CHRM3CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |